Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium

Alzheimer's & Dementia - Tập 9 - Trang 137-140 - 2013
Maria C. Carrillo1, Kaj Blennow2, Holly Soares3, Piotr Lewczuk4, Niklas Mattsson2, Pankaj Oberoi5, Robert Umek5, Manu Vandijck6, Salvatore Salamone7, Tobias Bittner8, Leslie M. Shaw9, Diane Stephenson10, Lisa Bain11, Henrik Zetterberg2,12
1Division Medical & Scientific Relations, Alzheimer's Association, Chicago, IL, USA
2Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Göteborg, Mölndal, Sweden
3Bristol Myers Squibb, Groton, CT, USA
4Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany
5Meso Scale Discovery, Gaithersburg, MD, USA
6Innogenetics, Ghent, Belgium
7Saladax Biomedical, Bethlehem, PA, USA
8Roche Diagnostics, Indianapolis, IN, USA
9Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
10Coalition Against Major Diseases, Critical Path Institute, Tucson, AZ, USA
11Elverson, PA, USA
12UCL Institute of Neurology, Queen Square, London, UK

Tóm tắt

Recognizing that international collaboration is critical for the acceleration of biomarker standardization efforts and the efficient development of improved diagnosis and therapy, the Alzheimer's Association created the Global Biomarkers Standardization Consortium (GBSC) in 2010. The consortium brings together representatives of academic centers, industry, and the regulatory community with the common goal of developing internationally accepted common reference standards and reference methods for the assessment of cerebrospinal fluid (CSF) amyloid β42 (Aβ42) and tau biomarkers. Such standards are essential to ensure that analytical measurements are reproducible and consistent across multiple laboratories and across multiple kit manufacturers. Analytical harmonization for CSF Aβ42 and tau will help reduce confusion in the AD community regarding the absolute values associated with the clinical interpretation of CSF biomarker results and enable worldwide comparison of CSF biomarker results across AD clinical studies.

Tài liệu tham khảo

10.1016/j.jalz.2011.03.005 Bjerke M, 2010, Confounding factors influencing amyloid beta concentration in cerebrospinal fluid, Int J Alzheimers Dis, 986310 10.1016/j.neulet.2006.07.009 10.1258/acb.2009.008232 10.2217/bmm.12.41 10.2217/bmm.12.39 Burton A, 2011, Big science for a big problem: ADNI enters its second phase, Lancet Neurol, 10, 206, 10.1016/S1474-4422(11)70031-X 10.1016/j.jalz.2011.05.2243
Thông tin
Thông tin xuất bản

Alzheimer's & Dementia

Tập 9

137-140

Thông tin tác giả